Back to Search
Start Over
Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous,low grade serous and low grade endometrioid ovarian cancer
- Source :
- Journal of Gynecology Obstetrics and Human Reproduction, Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50 (10), pp.102193. ⟨10.1016/j.jogoh.2021.102193⟩, Journal of Gynecology Obstetrics and Human Reproduction, Elsevier, 2021, 50 (10), pp.102193. ⟨10.1016/j.jogoh.2021.102193⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- International audience; BACKGROUND: The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients managed for stage I-IIa clear cell carcinoma, mucinous, low-grade serous and low-grade endometrioid ovarian cancer MATERIAL AND METHODS: Retrospective multicentre study of the research group FRANCOGYN between January 2001 and December 2018. All patients managed for stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer and for whom the presence of histological slides for the review of LVSI was available, were included. Patient’s characteristics with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A cox analysis for OS and RFS analysis were performed in all population. RESULTS: Over the study period, 133 patients were included in the thirteen institutions. Among them, 12 patients had LVSI (9%). LVSI was an independent predictive factor for poorer Overall and recurrence free survivals. LVSI affected OS (p
- Subjects :
- Oncology
endocrine system diseases
Lymphovascular invasion
Adjuvant chemotherapy
0302 clinical medicine
Overall survival
Stage (cooking)
Neoplasm Metastasis
Aged, 80 and over
Ovarian Neoplasms
education.field_of_study
030219 obstetrics & reproductive medicine
Obstetrics and Gynecology
Middle Aged
Prognosis
Adenocarcinoma, Mucinous
Lymphovascular
female genital diseases and pregnancy complications
3. Good health
Serous fluid
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Clear cell carcinoma
Female
France
Adult
medicine.medical_specialty
Adolescent
Lymphovascular space invasion
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics
Decision Support Techniques
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
Ovarian cancer
Internal medicine
medicine
Humans
education
[SDV.BDLR] Life Sciences [q-bio]/Reproductive Biology
Aged
Neoplasm Staging
Retrospective Studies
business.industry
[SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology
medicine.disease
Recurrence-free survival
Endometrial Neoplasms
[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics
Reproductive Medicine
business
Adenocarcinoma, Clear Cell
Subjects
Details
- Language :
- English
- ISSN :
- 24687847
- Database :
- OpenAIRE
- Journal :
- Journal of Gynecology Obstetrics and Human Reproduction, Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50 (10), pp.102193. ⟨10.1016/j.jogoh.2021.102193⟩, Journal of Gynecology Obstetrics and Human Reproduction, Elsevier, 2021, 50 (10), pp.102193. ⟨10.1016/j.jogoh.2021.102193⟩
- Accession number :
- edsair.doi.dedup.....64670dc8235aac628edee647cbd476d4